Table 1.
Biodistribution data of [18F]2 in nude mice bearing CHL-GLP-1 receptor positive tumor xenografts
| Organ or tissue | 30 min p.i. (n = 4) | 60 min p.i. (n = 4) | 60 min p.i. (n = 4) blockade | 120 min p.i. (n = 4) |
|---|---|---|---|---|
| %ID/g in | ||||
| Blood | 9.7 ± 1.1 | 6.9 ± 2.2 | 11.1 ± 0.6 | 3.3 ± 0.8 |
| Lungsa | 15.1 ± 1.5 | 15 ± 4 | 10.0 ± 0.4 | 11.4 ± 2.1 |
| Spleen | 2.9 ± 0.3 | 2.4 ± 0.8 | 3.5 ± 0.1 | 1.6 ± 0.5 |
| Kidneys | 33.3 ± 2.4 | 49 ± 18 | 79 ± 5 | 39 ± 12 |
| Pancreasa | 4.2 ± 0.6 | 4.4 ± 1.4 | 6 ± 4 | 3.2 ± 0.6 |
| Stomacha | 1.8 ± 0.7 | 1.3 ± 0.2 | 1.0 ± 0.1 | 1.0 ± 0.7 |
| Intestines | 3.0 ± 0.3 | 5.4 ± 0.8 | 5.3 ± 1.2 | 7 ± 4 |
| Liver | 6.4 ± 0.7 | 7.7 ± 2.1 | 10.60 ± 0.30 | 5.0 ± 1.1 |
| Muscle | 1.5 ± 0.4 | 1.1 ± 0.4 | 1.73 ± 0.13 | 0.61 ± 0.12 |
| Bone | 1.8 ± 0.3 | 2.0 ± 0.7 | 2.87 ± 0.20 | 1.9 ± 0.5 |
| Tumora | 15 ± 7 | 14 ± 7* | 7 ± 1* | 13 ± 10 |
Mice were injected with [18F]2 (200 kBq, 1.3 pmol) via the lateral tail vein. In the blockade group, each animal received nonradioactive precursor 1 (100 μg, 22 nmol) in PBS co-injected with tracer [18F]2 (266 kBq, 1.7 pmol)
*Values are significantly different (unpaired, two populations, Student t-test, P < 0.03)
aGLP-1 receptor-positive organs